AAAAAA
Results:
1-19
|
Results: 19
Authors:
Feagan, BG
Wong, CJ
Lau, CY
Wheeler, SL
Sue-A-Quan, G
Kirkley, A
Citation: Bg. Feagan et al., Transfusion practice in elective orthopaedic surgery, TRANSFUS M, 11(2), 2001, pp. 87-95
Authors:
Feagan, BG
Citation: Bg. Feagan, A controlled trial of a critical pathway for treating community-acquired pneumonia: The CAPITAL study, PHARMACOTHE, 21(7), 2001, pp. 89S-94S
Authors:
Sandborn, WJ
Feagan, BG
Hanauer, SB
Present, DH
Sutherland, LR
Kamm, MA
Wolf, DC
Baker, JP
Hawkey, C
Archambault, A
Bernstein, CN
Novak, C
Heath, PK
Targan, SR
Citation: Wj. Sandborn et al., An engineered human antibody to TNF (CDP571) for active Crohn's disease: Arandomized double-blind placebo-controlled trial, GASTROENTY, 120(6), 2001, pp. 1330-1338
Authors:
Feagan, BG
McDonald, JWD
Citation: Bg. Feagan et Jwd. Mcdonald, Mesalamine maintenance therapy for Crohn's disease, GASTROENTY, 120(2), 2001, pp. 585-585
Authors:
Feagan, BG
Citation: Bg. Feagan, Standard immunosuppression in IBD : current practice, ACT GASTR B, 64(2), 2001, pp. 182-188
Authors:
Feagan, BG
Citation: Bg. Feagan, Safety of biologics : current issues and future concerns, ACT GASTR B, 64(2), 2001, pp. 210-214
Authors:
Irvine, EJ
Greenberg, GR
Feagan, BG
Martin, F
Sutherland, LR
Thomson, ABR
Nilsson, LG
Persson, T
Citation: Ej. Irvine et al., Quality of life rapidly improves with budesonide therapy for active Crohn's disease, INFLAMM B D, 6(3), 2000, pp. 181-187
Authors:
Marrie, TJ
Lau, CY
Wheeler, SL
Wong, CJ
Feagan, BG
Citation: Tj. Marrie et al., Predictors of symptom resolution in patients with community-acquired pneumonia, CLIN INF D, 31(6), 2000, pp. 1362-1367
Authors:
Feagan, BG
Marrie, TJ
Lau, CY
Wheeler, SL
Wong, CJ
Vandervoort, MK
Citation: Bg. Feagan et al., Treatment and outcomes of community-acquired pneumonia at Canadian hospitals, CAN MED A J, 162(10), 2000, pp. 1415-1420
Authors:
Palmer, CS
Zhan, CL
Elixhauser, A
Halpern, MT
Rance, L
Feagan, BG
Marrie, TJ
Citation: Cs. Palmer et al., Economic assessment of the community-acquired pneumonia intervention trialemploying levofloxacin, CLIN THER, 22(2), 2000, pp. 250-264
Authors:
Marrie, TJ
Lau, CY
Wheeler, SL
Wong, CJ
Vandervoort, MK
Feagan, BG
Citation: Tj. Marrie et al., A controlled trial of a critical pathway for treatment of community-acquired pneumonia, J AM MED A, 283(6), 2000, pp. 749-755
Authors:
Feagan, BG
Marrie, TJ
Lau, CY
Wheeler, SL
Wong, CJ
Vandervoort, MK
Citation: Bg. Feagan et al., A critical pathway for treatment of community-acquired pneumonia - Reply, J AM MED A, 283(20), 2000, pp. 2655-2655
Authors:
Feagan, BG
Fedorak, RN
Irvine, EJ
Wild, G
Sutherland, L
Steinhart, AH
Greenberg, GR
Koval, J
Wong, CJ
Hopkins, M
Hanauer, SB
McDonald, JWD
Citation: Bg. Feagan et al., A comparison of methotrexate with placebo for the maintenance of remissionin Crohn's disease, N ENG J MED, 342(22), 2000, pp. 1627-1632
Authors:
Feagan, BG
Wong, CJ
Kirkley, A
Johnston, DWC
Smith, FC
Whitsitt, P
Wheeler, SL
Lau, CY
Johnston, W
Beaupre, L
Schaump, L
Bohonis, D
Greaves, K
Rorabeck, C
Bourne, R
Murkin, J
McCalden, R
MacDonald, S
McCabe, C
Smith, F
Dale, NI
Reynolds, L
Whitsitt, P
Rochon, N
Taylor, D
O'Farrell, TA
Boyce, D
Pisesky, W
O'Connor, G
LeNoble, E
Mantle, M
Bond, D
Turner, K
Bond, P
Swilzer, K
Laflamme, GH
Pynn, B
Dow, G
Steeves, J
Clark, A
Pavlatos-Jones, G
MacLoughlin, C
Laliberte, P
Grenier, A
Chabot, J
Lortie, M
Godin, C
Pynn, B
Waddell, J
Morton, J
Sandler, A
Kaszas, Z
Warriner, B
Werry, D
Metcalfe, C
Tile, M
Dubrovskis, V
Garnett, R
Krepski, B
Cicutti, N
Huk, O
Pynn, B
Wilson, J
Johnston, N
Mulock, R
Sarazin, B
Liddiard, E
Bergman, B
Johnson, W
Citation: Bg. Feagan et al., Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty - A randomized, controlled trial, ANN INT MED, 133(11), 2000, pp. 845-854
Authors:
Feagan, BG
Vreeland, MG
Larson, LR
Bala, MV
Citation: Bg. Feagan et al., Annual cost of care for Crohn's disease: A payor perspective, AM J GASTRO, 95(8), 2000, pp. 1955-1960
Authors:
Feagan, BG
Citation: Bg. Feagan, Review article: economic issues in Crohn's disease - assessing the effectsof new treatments on health-related quality of life, ALIM PHARM, 13, 1999, pp. 29-37
Authors:
Sandborn, WJ
Tremaine, WJ
Wolf, DC
Targan, SR
Sninsky, CA
Sutherland, LR
Hanauer, SB
McDonald, JWD
Feagan, BG
Fedorak, RN
Isaacs, KL
Pike, MG
Mays, DC
Lipsky, JJ
Gordon, S
Kleoudis, CS
Murdock, RH
Citation: Wj. Sandborn et al., Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease, GASTROENTY, 117(3), 1999, pp. 527-535
Authors:
Silverstein, MD
Loftus, EV
Sandborn, WJ
Tremaine, WJ
Feagan, BG
Nietert, PJ
Harmsen, WS
Zinsmeister, AR
Citation: Md. Silverstein et al., Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort, GASTROENTY, 117(1), 1999, pp. 49-57
Authors:
Feagan, BG
Citation: Bg. Feagan, Aminosalicylates for active disease and in the maintenance of remission inCrohn's disease, EURO J SURG, 164(12), 1998, pp. 903-909
Risultati:
1-19
|